Please login to the form below
endometrial cancer
This page shows the latest endometrial cancer news and features for those working in and with pharma, biotech and healthcare.
Merck’s Keytruda receives FDA approval for advanced endometrial cancer
Merck &Co – known as MSD outside the US and Canada – has announced that Keytruda (pembrolizumab) has been approved by the US Food and Drug Administration (FDA) for advanced endometrial cancer. ... Endometrial cancer is the most common type of uterine
Latest news
-
AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
Small cell lung cancer accounts for 15% of all lung cancers and has a poor prognosis. ... tract cancer, oesophageal cancer, gastric and gastroesophageal cancer, cervical cancer, ovarian cancer, endometrial cancer, and other solid tumours.
-
FDA approval for Roche diagnostic solid tumour test
In April 2021, GSK received US approval for PD-1 inhibitor Jemperli for the treatment of endometrial cancer, following an FDA-approved test. ... GSK acquired Jemperli as part of its $5.1bn acquisition of cancer specialist Tesaro, although the drug was
-
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
Merck &Co – known as MSD outside the US and Canada – and Eisai have announced that their immunotherapy combination Keytruda plus Lenvima has been approved in the US to treat endometrial cancer. ... The Keytruda plus Lenvima was previously approved
-
NICE recommends Keytruda for colorectal cancer patients with rare mutations
There are currently no specific treatments for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. ... Cells that are mismatch repair (MMR) deficient often have many DNA mutations, and are commonly
-
GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer
British pharma company GlaxoSmithKline (GSK) has received US approval for its PD-1 inhibitor Jemperli for the treatment of endometrial cancer. ... Endometrial cancer has the highest rate of dMMR among solid tumour types, with approximately 25% bearing
More from news
Approximately 3 fully matching, plus 17 partially matching documents found.
Latest from PMHub
-
The power of influence in transforming women’s health
HRT continued to grow in popularity after the 1960s, particularly with research showing the links between certain doses and a reduced risk of endometrial cancer. ... iv] Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- A new era for UK-Japanese scientific research relations
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
